We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc Health Enhances Prism Platform for Better Virtual Care
Read MoreHide Full Article
Teladoc Health, Inc. (TDOC - Free Report) recently introduced new enhancements to its proprietary care delivery platform, Prism. The platform has enabled the company to achieve a competitive edge due to its extensive reach and capability to provide a wide range of high-quality virtual healthcare services.
As a result of the new advancements, the platform now features improved data integration and administrative tools that automatically identify and highlight recommended screenings and diagnostic assessments. This ensures that Teladoc Health’s care teams have access to key insights, enabling them to address health gaps more effectively during patient interactions. Additionally, clinicians and health coaches can now seamlessly access member eligibility information and refer patients to Teladoc Health’s Connected Care Partners.
Another significant advancement is the expanded closed-loop referral functionality, which now allows Teladoc Health care teams to connect patients with in-network community care providers. Previously, this feature was exclusive to the company’s Primary360 program. To further enhance clinical efficiency, the platform has also introduced AI-powered clinical transcription tools that streamline documentation. These tools capture and structure patient notes in real time, ensuring high-quality record-keeping while reducing the administrative burden for healthcare providers.
The recently introduced enhancements are designed to improve care coordination with digital health partners and community healthcare providers. The upgraded platform facilitates more efficient referrals to Teladoc Health’s digital and in-person care networks while leveraging data-driven insights to enhance virtual care visits. By enabling clinicians to address care gaps more effectively, these updates support improved health outcomes for individuals covered by employer-sponsored and health plan services.
Benefits of the Recent Move to Teladoc Health
The lucrativeness of the Prism platform is expected to get a boost as a result of the recent capability additions. This, in turn, may attract more members to TDOC and subsequently boost revenues of its Integrated Care segment in the days ahead. Revenues in the segment improved 4% year over year in 2024.
Currently, more than 93 million Americans have access to at least one Teladoc Health offering through their employer or health plan. The efficiency of its proprietary care delivery platform enables 90% of Teladoc Health’s virtual urgent care visits to be completed within 30 minutes of a member’s outreach.
TDOC’s Share Price Performance & Zacks Rank
Shares of Teladoc Health have gained 57.6% year to date compared with the industry’s 2.2% growth. TDOC currently carries a Zacks Rank #3 (Hold).
Option Care’s earnings surpassed the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 15.91%. The consensus estimate for OPCH’s 2025 earnings indicates a rise of 38.2%, while the consensus mark for revenues implies an improvement of 8.3% from the corresponding year-ago figures.
The consensus estimate for OPCH’s 2025 earnings has moved 34.9% north in the past seven days. Shares of Option Care have gained 49% year to date.
Ensign Group’s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 1.48%. The consensus estimate for ENSG’s 2025 earnings indicates a rise of 12.7% from the year-ago figure. The consensus mark for revenues indicates growth of 14.3% from the year-ago figure.
The consensus estimate for ENSG’s 2025 earnings has moved 2% north in the past 30 days. Shares of Ensign Group have lost 2.6% year to date.
BioMarin Pharmaceutical’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 32.36%. The consensus estimate for BMRN’s 2025 earnings indicates a rise of 20.5%, while the consensus mark for revenues implies an improvement of 10% from the corresponding year-ago figures.
The Zacks Consensus Estimate for BMRN’s 2025 earnings has moved 1.2% north in the past seven days. Shares of BioMarin Pharmaceutical have rallied 7.6% year to date.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Shutterstock
Teladoc Health Enhances Prism Platform for Better Virtual Care
Teladoc Health, Inc. (TDOC - Free Report) recently introduced new enhancements to its proprietary care delivery platform, Prism. The platform has enabled the company to achieve a competitive edge due to its extensive reach and capability to provide a wide range of high-quality virtual healthcare services.
As a result of the new advancements, the platform now features improved data integration and administrative tools that automatically identify and highlight recommended screenings and diagnostic assessments. This ensures that Teladoc Health’s care teams have access to key insights, enabling them to address health gaps more effectively during patient interactions. Additionally, clinicians and health coaches can now seamlessly access member eligibility information and refer patients to Teladoc Health’s Connected Care Partners.
Another significant advancement is the expanded closed-loop referral functionality, which now allows Teladoc Health care teams to connect patients with in-network community care providers. Previously, this feature was exclusive to the company’s Primary360 program. To further enhance clinical efficiency, the platform has also introduced AI-powered clinical transcription tools that streamline documentation. These tools capture and structure patient notes in real time, ensuring high-quality record-keeping while reducing the administrative burden for healthcare providers.
The recently introduced enhancements are designed to improve care coordination with digital health partners and community healthcare providers. The upgraded platform facilitates more efficient referrals to Teladoc Health’s digital and in-person care networks while leveraging data-driven insights to enhance virtual care visits. By enabling clinicians to address care gaps more effectively, these updates support improved health outcomes for individuals covered by employer-sponsored and health plan services.
Benefits of the Recent Move to Teladoc Health
The lucrativeness of the Prism platform is expected to get a boost as a result of the recent capability additions. This, in turn, may attract more members to TDOC and subsequently boost revenues of its Integrated Care segment in the days ahead. Revenues in the segment improved 4% year over year in 2024.
Currently, more than 93 million Americans have access to at least one Teladoc Health offering through their employer or health plan. The efficiency of its proprietary care delivery platform enables 90% of Teladoc Health’s virtual urgent care visits to be completed within 30 minutes of a member’s outreach.
TDOC’s Share Price Performance & Zacks Rank
Shares of Teladoc Health have gained 57.6% year to date compared with the industry’s 2.2% growth. TDOC currently carries a Zacks Rank #3 (Hold).
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks in the Medical space are Option Care Health, Inc. (OPCH - Free Report) , The Ensign Group, Inc. (ENSG - Free Report) and BioMarin Pharmaceutical Inc. (BMRN - Free Report) . While Option Care currently sports a Zacks Rank #1 (Strong Buy), Ensign Group and BioMarin Pharmaceutical carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Option Care’s earnings surpassed the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 15.91%. The consensus estimate for OPCH’s 2025 earnings indicates a rise of 38.2%, while the consensus mark for revenues implies an improvement of 8.3% from the corresponding year-ago figures.
The consensus estimate for OPCH’s 2025 earnings has moved 34.9% north in the past seven days. Shares of Option Care have gained 49% year to date.
Ensign Group’s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 1.48%. The consensus estimate for ENSG’s 2025 earnings indicates a rise of 12.7% from the year-ago figure. The consensus mark for revenues indicates growth of 14.3% from the year-ago figure.
The consensus estimate for ENSG’s 2025 earnings has moved 2% north in the past 30 days. Shares of Ensign Group have lost 2.6% year to date.
BioMarin Pharmaceutical’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 32.36%. The consensus estimate for BMRN’s 2025 earnings indicates a rise of 20.5%, while the consensus mark for revenues implies an improvement of 10% from the corresponding year-ago figures.
The Zacks Consensus Estimate for BMRN’s 2025 earnings has moved 1.2% north in the past seven days. Shares of BioMarin Pharmaceutical have rallied 7.6% year to date.